Oppenheimer Initiates Coverage on MediWound (NASDAQ:MDWD)
Analysts at Oppenheimer initiated coverage on shares of MediWound (NASDAQ:MDWD – Get Free Report) in a note issued to investors on Monday. The brokerage set an “outperform” rating and a $34.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price objective would indicate a potential upside of 57.48% from the company’s previous close. MDWD has […]
Analysts at Oppenheimer initiated coverage on shares of MediWound (NASDAQ:MDWD – Get Free Report) in a note issued to investors on Monday. The brokerage set an “outperform” rating and a $34.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price objective would indicate a potential upside of 57.48% from the company’s previous close. MDWD has […]
